GLP-1 Agonists and Cardiovascular Outcomes: What the LEADER and SUSTAIN-6 Trials Really Prove

Why Cardiovascular Outcomes Matter More Than Glucose Control

For decades, the dominant paradigm in type 2 diabetes management was simple: lower blood sugar and hope the complications followed. Landmark trials like ACCORD and ADVANCE complicated that picture considerably. Aggressive glycemic control reduced microvascular events — retinopathy, neuropathy, nephropathy — but failed to move the needle meaningfully on the outcomes patients feared most: heart attacks, strokes, and cardiovascular death.

The inflection point came in 2008, when the FDA mandated that all new diabetes drugs demonstrate cardiovascular safety through dedicated large-scale outcome trials. What followed was a decade of clinical science that reshaped endocrinology entirely. GLP-1 receptor agonists — which had been approved primarily as glucose-lowering agents — turned out to be something far more consequential: genuine cardioprotective drugs.

The LEADER trial in 2016 was the first major signal. Liraglutide, a once-daily injectable GLP-1 agonist, reduced major adverse cardiovascular events (MACE) by a statistically significant margin versus placebo in patients with type 2 diabetes and established cardiovascular disease. Published simultaneously in the New England Journal of Medicine, SUSTAIN-6 replicated that finding with the longer-acting once-weekly semaglutide. The scientific community's response was swift: these were not just diabetes drugs. They were cardiovascular drugs that happened to control blood sugar.

Defining the MACE Endpoint

All cardiovascular outcome trials in diabetes use a composite endpoint called MACE — Major Adverse Cardiovascular Events. The "3-point MACE" definition encompasses: non-fatal myocardial infarction, non-fatal stroke, and cardiovascular death. Some trials use a 4-point MACE adding heart failure hospitalization. Understanding this composite is critical for interpreting the trial data: a 13% or 26% reduction in 3-point MACE represents a meaningful, clinically significant benefit across a patient population already carrying high baseline risk.

The LEADER Trial: Liraglutide's Cardiovascular Proof

The LEADER trial (Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results) enrolled 9,340 patients with type 2 diabetes across 32 countries. Participants had either established cardiovascular disease (prior MI, stroke, peripheral arterial disease, or heart failure) or at least two cardiovascular risk factors. The trial ran a median of 3.8 years, with patients randomized to liraglutide 1.8 mg daily or placebo on top of standard diabetes care.

Primary Outcomes: A Landmark Finding

The primary composite endpoint — first occurrence of cardiovascular death, non-fatal MI, or non-fatal stroke — occurred in 13.0% of liraglutide patients versus 14.9% of placebo patients, yielding a hazard ratio of 0.87 (95% CI 0.78–0.97, p=0.01 for superiority). This 13% relative risk reduction was driven predominantly by a robust reduction in cardiovascular mortality.

Cardiovascular death was reduced by 22% (HR 0.78, 95% CI 0.66–0.93, p=0.007). This is arguably the most clinically meaningful finding in the entire trial — hard cardiovascular death endpoints are notoriously difficult to move. All-cause mortality was also significantly reduced, by 15% (HR 0.85, 95% CI 0.74–0.97).

Non-Fatal MI and Stroke Results

Individual components of the MACE composite showed numerical reductions that did not reach independent statistical significance, a common pattern in cardiovascular outcome trials where the composite is powered but individual components are not. Non-fatal MI trended lower in the liraglutide group (6.0% vs 6.8%), and non-fatal stroke rates were similar between groups (3.4% vs 3.8%). The stroke signal was notably weaker for liraglutide compared to what SUSTAIN-6 would later show for semaglutide.

Renal Protection Signal in LEADER

A pre-specified secondary endpoint assessed new or worsening nephropathy, defined as the development of persistent macroalbuminuria, doubling of serum creatinine with eGFR ≤45 mL/min, renal replacement therapy, or renal death. Liraglutide reduced this composite by 22% (HR 0.78, 95% CI 0.67–0.92, p=0.003). The benefit was primarily driven by a 26% reduction in the development of persistent macroalbuminuria — an early and important marker of diabetic nephropathy progression.

SUSTAIN-6: Semaglutide's Cardiovascular Edge

SUSTAIN-6 (Trial to Evaluate Cardiovascular and Other Long-term Outcomes with Semaglutide in Subjects with Type 2 Diabetes) enrolled 3,297 patients — smaller than LEADER but designed as a non-inferiority safety trial that exceeded expectations. Patients were randomized to subcutaneous semaglutide 0.5 mg or 1.0 mg weekly versus placebo for a median of 2.1 years. As in LEADER, participants had high baseline cardiovascular risk.

The 26% MACE Reduction Explained

SUSTAIN-6's headline result: semaglutide reduced 3-point MACE by 26% relative to placebo (HR 0.74, 95% CI 0.58–0.95, p<0.001 for non-inferiority; p=0.02 for superiority). Given the shorter duration and smaller sample, this magnitude of effect was striking. The event rates were 6.6% for semaglutide versus 8.9% for placebo.

A Particularly Strong Stroke Signal

Unlike LEADER, SUSTAIN-6 showed a pronounced and statistically significant reduction in non-fatal stroke — down 39% (HR 0.61, 95% CI 0.38–0.99, p=0.04). This stroke benefit was unexpected in its magnitude and has since driven considerable interest in GLP-1 mechanisms related to cerebrovascular protection, endothelial function, and atherosclerotic plaque stabilization in carotid arteries.

Non-fatal MI was also numerically reduced by 26% (HR 0.74, 95% CI 0.51–1.08), though this did not reach statistical significance in isolation. Cardiovascular death rates were similar between groups, unlike the clear mortality reduction seen in LEADER.

SUSTAIN-6 Renal Outcomes

Semaglutide also showed robust renal benefits in SUSTAIN-6. New or worsening nephropathy was reduced by 36% (HR 0.64, 95% CI 0.46–0.88, p=0.005). The effect was again driven by reduction in macroalbuminuria development, consistent with the hypothesis that GLP-1 agonists reduce glomerular hyperfiltration and tubuloglomerular feedback dysregulation that drives early diabetic nephropathy.

Evidence Table: Key GLP-1 Cardiovascular Outcome Trials

Mechanisms of Cardiovascular Protection

Understanding why GLP-1 agonists reduce cardiovascular events requires moving beyond the glucose-lowering narrative. Multiple overlapping mechanisms likely contribute, and disentangling their relative importance remains an active area of research.

Blood Pressure Reduction

GLP-1 receptor agonists consistently reduce systolic blood pressure by 2–5 mmHg in clinical trials, even independent of weight loss. The mechanisms include natriuresis (increased sodium excretion by the kidney), direct vasodilatory effects on vascular smooth muscle, and possible central nervous system modulation of sympathetic tone. While modest in absolute terms, sustained blood pressure reduction across a population of high-risk patients translates to meaningful reductions in stroke and MI risk.

Lipid Profile Improvement

GLP-1 agonist therapy is associated with reductions in LDL cholesterol (typically 3–5%), total cholesterol, and particularly triglycerides (often 10–15% reductions). The triglyceride effect is thought to reflect reduced hepatic very-low-density lipoprotein (VLDL) production and possibly reduced chylomicron synthesis. While these lipid effects are modest compared to statins, they complement the overall cardiovascular risk reduction profile.

Anti-Inflammatory and Plaque-Stabilizing Effects

Perhaps the most mechanistically compelling explanation for the observed stroke reduction in SUSTAIN-6 is GLP-1's anti-inflammatory effect on atherosclerotic plaque. GLP-1 receptors are expressed on macrophages within atherosclerotic lesions. In preclinical models, GLP-1 agonism reduces macrophage foam cell formation, decreases inflammatory cytokine secretion (TNF-alpha, IL-6), and promotes more stable "fibrous cap" plaque morphology with less necrotic core — the characteristics of plaques less likely to rupture and cause acute thrombotic events.

Human carotid intima-media thickness (CIMT) studies with liraglutide support plaque-stabilizing activity in vivo, though this remains a surrogate measure rather than a hard endpoint.

Direct Cardiac Effects

GLP-1 receptors are expressed in cardiac tissue, including cardiomyocytes and coronary endothelium. Preclinical data show that GLP-1 agonism improves cardiac contractility, reduces ischemia-reperfusion injury, and promotes cardioprotective gene expression. However, translating these findings to clear clinical benefit in trials of heart failure has been more complicated — a topic worth addressing directly.

Weight Loss and Reduced Cardiac Workload

The weight loss achieved with GLP-1 agonists — typically 5–10% of body weight with once-weekly semaglutide in a diabetes population, and up to 15% with high-dose semaglutide in obesity trials — reduces cardiac workload through multiple pathways: lower adipose tissue mass reduces circulating blood volume and cardiac output demands; visceral fat reduction decreases systemic inflammation and improves insulin sensitivity; and reduced body weight lowers left ventricular wall stress. In patients with heart failure with preserved ejection fraction (HFpEF), where obesity is a dominant pathophysiological driver, the STEP-HFpEF trial demonstrated that semaglutide significantly improved exercise capacity and quality of life.

Heart Failure: The Nuanced Picture

Heart failure occupies a complicated position in the GLP-1 cardiovascular story. Early mechanistic optimism was tempered by the FIGHT trial, which showed that liraglutide in patients with heart failure with reduced ejection fraction (HFrEF) not only failed to improve outcomes but trended toward harm — with higher rates of death and HF hospitalization in the liraglutide group. This finding led to caution about GLP-1 agonists in HFrEF specifically.

HFrEF vs HFpEF: A Critical Distinction

The divergence between HFrEF and HFpEF responses to GLP-1 agonists likely reflects fundamental differences in pathophysiology. HFrEF is characterized by cardiomyocyte loss and reduced systolic function, where the chronotropic and inotropic effects of GLP-1 receptor activation may be unfavorable or at best neutral. HFpEF, increasingly recognized as an obesity-driven disorder of diastolic dysfunction, inflammation, and metabolic dysregulation, appears far more responsive to GLP-1-mediated weight loss and anti-inflammatory effects.

The STEP-HFpEF trial (2023) was a landmark: semaglutide 2.4 mg weekly in obese patients with HFpEF produced a 13.3-point improvement in Kansas City Cardiomyopathy Questionnaire (KCCQ) scores, 6-minute walk distance improved by 21.5 meters, and body weight fell by 13.3% — all significantly better than placebo. The cardiovascular outcomes community is now reconceptualizing GLP-1 agonists as a first-line option in HFpEF with obesity, a condition for which therapeutic options have historically been limited.

Heart Failure Hospitalization in LEADER and SUSTAIN-6

Both trials showed neutral effects on heart failure hospitalization as an individual endpoint, although the SELECT trial in a non-diabetic obesity population subsequently showed a nominally significant reduction in heart failure hospitalization. The current clinical synthesis is: GLP-1 agonists are not primary HF drugs for most patients, but they are safe in high-risk cardiovascular populations and confer meaningful benefit in HFpEF driven by obesity.

Renal Protection: The FLOW Trial and Mechanism

The 2024 FLOW trial (Evaluate Renal Function with Semaglutide Once Weekly) was the first cardiovascular and renal outcome trial designed specifically to test a GLP-1 agonist's kidney-protective effects. In 3,533 patients with type 2 diabetes and chronic kidney disease (eGFR 50–75 mL/min/1.73m² or eGFR 25–50 with UACR ≥300 mg/g), semaglutide 1.0 mg weekly versus placebo was studied.

Results were striking: semaglutide reduced the primary composite kidney endpoint (sustained decline in eGFR ≥50%, kidney failure, or renal or CV death) by 24% (HR 0.76). eGFR decline was slowed by 1.16 mL/min/1.73m² per year — modest in absolute terms but meaningful over decades of kidney disease. Importantly, the trial was stopped early for efficacy, underscoring the strength of the renal protection signal.

Mechanisms of GLP-1 Renal Protection

Renal protection from GLP-1 agonists likely involves: reduction in intraglomerular pressure through tubuloglomerular feedback modulation (similar but distinct from SGLT2 inhibitors); anti-inflammatory effects reducing glomerular mesangial expansion; blood pressure lowering; and improved metabolic milieu reducing advanced glycation end-product formation. The combination of GLP-1 agonists with SGLT2 inhibitors, which protect the kidney through complementary mechanisms, is now considered standard of care for patients with type 2 diabetes and chronic kidney disease.

SELECT Trial: Expanding Beyond Diabetes

The SELECT trial (Semaglutide Effects on Cardiovascular Outcomes in People With Overweight or Obesity) was a paradigm shift. Published in 2023, it enrolled 17,604 patients who were obese or overweight but had no diabetes — only established cardiovascular disease. Semaglutide 2.4 mg weekly (the dose used in the WEGOVY obesity indication) reduced 3-point MACE by 20% over a mean follow-up of 3.3 years.

This trial demolished the assumption that GLP-1 cardiovascular benefits were merely a downstream effect of better glucose control. In a population without diabetes, glycemic effects were negligible — yet the cardiovascular protection was robust and statistically unambiguous. The SELECT findings strongly suggest that GLP-1 receptor agonism itself, or the weight loss it produces, carries intrinsic cardioprotective properties extending far beyond the metabolic context of type 2 diabetes.

Implications for Clinical Practice

SELECT has prompted serious reconsideration of how GLP-1 agonists should be classified: as diabetes drugs with cardiac benefits, or as cardiovascular drugs with metabolic benefits? The 2024 ACC/AHA guidelines for obesity-related cardiovascular disease now include specific language supporting GLP-1 agonist use for cardiovascular risk reduction in obese patients with established CVD, regardless of diabetes status — a remarkable expansion of indication from where these drugs stood just a decade ago.

Atherosclerosis Mechanisms: The Plaque Science

Beyond clinical trial endpoints, the mechanistic understanding of how GLP-1 agonists interact with atherosclerosis has advanced substantially through imaging substudies, ex vivo plaque analysis, and animal models. The picture that emerges is one of multifactorial plaque stabilization rather than simple lipid lowering.

Endothelial Protection

GLP-1 receptors on vascular endothelial cells mediate upregulation of nitric oxide synthase (eNOS), increasing nitric oxide bioavailability. Nitric oxide is central to endothelial health: it inhibits platelet aggregation, reduces leukocyte adhesion, maintains vasodilatory tone, and suppresses vascular smooth muscle proliferation — all processes that, when dysregulated, drive atherosclerotic progression. Liraglutide treatment in patients with type 2 diabetes has been shown to improve flow-mediated dilation (FMD), a measure of endothelial function, independent of HbA1c improvement.

Monocyte and Macrophage Modulation

Atherosclerotic plaques are macrophage-rich inflammatory lesions. GLP-1 receptors expressed on monocytes and tissue macrophages, when activated, shift these cells toward anti-inflammatory M2 polarization and away from the pro-inflammatory M1 phenotype that drives plaque vulnerability. GLP-1 agonism also reduces monocyte recruitment to the vascular wall by downregulating adhesion molecule expression (VCAM-1, ICAM-1) on endothelial cells — the first step in plaque formation.

Oxidative Stress Reduction

Reactive oxygen species (ROS) generated in the setting of hyperglycemia and metabolic dysregulation oxidize LDL cholesterol to oxLDL — the primary driver of macrophage foam cell formation and plaque necrosis. GLP-1 agonism activates antioxidant pathways via cAMP/PKA signaling, reducing intracellular ROS accumulation in both endothelial cells and macrophages. This mechanistic layer provides a compelling explanation for why glycemic improvements alone cannot account for the cardiovascular benefits observed — the receptor-level signaling itself is doing cardioprotective work.

Comparing GLP-1 Agents: Which Has the Best Cardiovascular Evidence?

Not all GLP-1 receptor agonists have demonstrated cardiovascular superiority in outcome trials. It is important to distinguish agents with proven benefit from those with neutral results or less evidence.

Semaglutide (Ozempic/Wegovy) has the broadest and most compelling cardiovascular evidence base, spanning SUSTAIN-6 (diabetic population), SOUL (oral semaglutide vs placebo), and SELECT (non-diabetic obesity). Its once-weekly dosing, strong HbA1c and weight reduction, and consistency of CV benefit across multiple trials make it the most well-supported agent.

Liraglutide (Victoza) demonstrated clear CV death reduction in LEADER — arguably the hardest and most clinically meaningful endpoint of any GLP-1 trial. Its once-daily dosing is a practical disadvantage versus weekly semaglutide, but its mortality benefit is robust and reproducible.

Dulaglutide (Trulicity) showed a modest 12% MACE reduction in REWIND, with the notable distinction of including a primary prevention population (patients without established CVD), suggesting possible broader applicability. However, the effect size is smaller and less convincingly driven by hard endpoints.

Exenatide (Bydureon) showed neutral CV outcomes in EXSCEL — no superiority over placebo. This is consistent with shorter-acting GLP-1 agonists or agents with lower receptor occupancy providing less robust plaque-stabilizing benefit.

Lixisenatide showed neutral outcomes in ELIXA. The pattern across trials suggests that drug-specific pharmacology — receptor binding affinity, half-life, penetration into atherosclerotic plaque tissue — drives differential CV outcomes, not simply the GLP-1 mechanism class itself.

Frequently Asked Questions

Can GLP-1 agonists replace statins for cardiovascular protection?

No. Statin therapy remains the cornerstone of cardiovascular risk reduction for patients with established or high-risk CVD. The LDL-lowering achieved by statins (typically 30–50% or more) far exceeds the modest lipid effects of GLP-1 agonists. The cardiovascular benefits of GLP-1 drugs are additive to statins, not substitutive. Guidelines recommend maximizing statin therapy before or alongside GLP-1 initiation in high-risk patients.

How quickly do cardiovascular benefits appear with GLP-1 therapy?

Kaplan-Meier curves from LEADER and SUSTAIN-6 show separation between active and placebo groups beginning at roughly 12–18 months of therapy. This timing is consistent with a mechanism requiring sustained drug exposure for plaque stabilization and metabolic remodeling, rather than an acute drug effect. Patients should understand that cardiovascular benefit accrues over years, not weeks.

Are oral GLP-1 agonists (oral semaglutide) as effective as injectables for CV outcomes?

The SOUL trial (2024) studied oral semaglutide 14 mg daily versus placebo in type 2 diabetes patients with CVD, showing a statistically significant MACE reduction. This is encouraging but with a caveat: oral semaglutide achieves substantially lower bioavailability (1–2%) compared to subcutaneous formulations, requiring specific administration protocols (morning fasting, small water volume). The CV benefit appears real but may be smaller in absolute terms than injectable semaglutide at equivalent receptor engagement.